Medyczne Centrum Hetmanska Piotr Leszczynski

At Medyczne Centrum Hetmanska Piotr Leszczynski researchers are concentrating on autoimmune disorders, particularly Active Systemic Lupus Erythematosus. The study seeks to determine whether a new oral kinase inhibitor can provide greater improvement in disease activity compared with placebo.

• Evaluation of a novel kinase inhibitor for SLE
• Assessment of disease activity using standardized response indices

Located in Poznan, Poland, the hospital currently runs two investigator‑led trials in this therapeutic area, aiming to expand treatment options for patients with immune‑mediated disease.

The department also focuses on systemic sclerosis, a connective‑tissue condition that can impair lung function and cause widespread symptoms. Ongoing research evaluates whether a new oral compound can slow the decline in forced vital capacity and improve overall disease burden.

• Investigation of lung function preservation in systemic sclerosis
• Exploration of systemic symptom improvement with novel therapy

These studies contribute to broadening therapeutic choices for patients with severe skin and connective‑tissue disease at the Poznan hospital.